Reacción medicamentosa disfrazada de metástasis erisipeloide

• Sofía Torres-Figueroa ^[1] ; Héctor Pérez ^[1] ; Melanie Villamizar ^[1]
  1. [1] Universidad Nacional de Colombia

     Universidad Nacional de Colombia

     Colombia

     
• Localización: Piel: Formación continua en dermatología, ISSN 0213-9251, Vol. 41, Nº. 3 (Marzo), 2026, págs. 258-259
• Idioma: español
• DOI: 10.1016/j.piel.2025.08.001
• Títulos paralelos:
  • Drug reaction masquerading as erysipeloid carcinoma
• Texto completo no disponible (Saber más ...)
• Referencias bibliográficas
  • Patrinely JR, Baker LX, Davis EJ, et al. Outcomes after progression of disease with anti-PD-1/PDL1 therapy for advanced melanoma. Cancer....
  • Mital R, Cartron AM, Trinidad JC, et al. Novel cutaneous eruptions in the setting of programmed cell death protein 1 inhibitor therapy. JAAD...
  • Eggermont AM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–1801.
  • Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol....
  • Shaker G, Mehendale T, De La Rosa C. Fixed drug eruption: an underrecognized cutaneous manifestation of a drug reaction in the primary care...